Training Example: MOVANTIK – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

MOVANTIK

(https://movantik.com) 📸 Data Snapshot: May 24, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE (https://movantik.com)
H1 MOVANTIK gets you moving.
H2 SELECT IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
H3 If you’re taking opioids and are constipated, don’t suffer in silence.
H5 APPROVED USE FOR MOVANTIK
H5 IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
NAV_HEADER_REPEATED (https://movantik.com/hcp/)
H1 Anticipate OIC.Treat with confidence.
H2 SELECT IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
H5 INDICATIONS AND USAGE
H5 IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
H5 CONTRAINDICATIONS
H5 WARNINGS AND PRECAUTIONS
H5 ADVERSE REACTIONS
H5 DRUG INTERACTIONS
H5 USE IN SPECIFIC POPULATIONS
NAV_HEADER_HEADING_REPEATED_BODY (https://movantik.com/about/)
H1 Rapid response with MOVANTIK
H2 In adults with chronic non-cancer pain, MOVANTIK 25 mg was shown to be effective for OIC in 2 clinical studies.1,2
H2 SELECT IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
H5 APPROVED USE FOR MOVANTIK
H5 IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
NAV_HEADER_HEADING_REPEATED_BODY (https://movantik.com/burden-of-oic/)
H1 You’re not alone.OIC is prevalent—yetundertreated.
H2 SELECT IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
H3 Don’t bear the burden of OIC alone – relief can begin with a conversation1,*
H5 APPROVED USE FOR MOVANTIK
H5 IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://movantik.com)
When opioid constipation slows you down,
[H1] MOVANTIK gets you moving.
[IMG: Number 1 Prescribed Oral Treatment of its kind]
[H3] If you’re taking opioids and are constipated, don’t suffer in silence.
Find out if MOVANTIK is right for youSame-day relief is possible.Find out howSave with MOVANTIKReferences: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Data on file. Prescription data. Valinor Pharma, LLC; 2023.
449 chars
SUB-PAGE · THIN (https://movantik.com/hcp/)
For patients experiencing constipation from opioids for chronic non-cancer pain
[H1] Anticipate OIC.Treat with confidence.
[IMG: Number 1 Prescribed Oral Treatment of its kind]
Is it possible your patients are suffering silently from OIC?References: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Data on file. Prescription data. Valinor Pharma, LLC; 2023.
390 chars
SUB-PAGE · THIN (https://movantik.com/about/)
About MOVANTIK
[H1] Rapid response with MOVANTIK
[H2] In adults with chronic non-cancer pain, MOVANTIK 25 mg was shown to be effective for OIC in 2 clinical studies.1,2
In these studies, MOVANTIK worked quickly, often within 6-12 hours of the first dose1
[IMG: MOVANTIK in the AM may lead to Bowel movement in the PM]
References: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396.
587 chars
SUB-PAGE (https://movantik.com/burden-of-oic/)
Burden of OICSuffering from opioid-induced constipation?
[H1] You’re not alone.OIC is prevalent—yetundertreated.
[H3] Don’t bear the burden of OIC alone – relief can begin with a conversation1,*
[IMG: chart]
[IMG: chart]
*In an analysis of a multinational longitudinal study of 493 patients with chronic non-cancer pain and clinician-identified, patient-confirmed OIC.1†Constipation treatments included OTC laxatives (stool softeners, osmotics, stimulants, salines, and rectal options), prescription laxatives, and behavioral therapies (fiber supplements, increased fluids and exercise, and dietary changes). 29% of patients in the study reported “much benefit” from constipation treatments.1OTC treatment is usually not enough6References: 1. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269-281. 2. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42. 3. Abramowitz L, Beziaud N, Labreze L. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16(2):1423-1433. 4. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380. 5. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Clinical Guidelines Committee. Gastroenterology. 2019;156:218-226. 6. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-1865.
1957 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
2Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/hcp/ 0 0
/about/ 0 0
/burden-of-oic/ 2 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/hcp/ — no schema detected (entity gap)
/about/ — no schema detected (entity gap)
/burden-of-oic/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: MOVANTIK (movantik.com)

https://movantik.com 📍 Industry: Medical Devices, Pharma & Biotech
25 BS / 100

This is a rare case of a ‘marketing-first’ appearance that actually possesses the necessary receipts. While the slogans are generic pharma-speak, the granular clinical data and bibliographic rigor result in a very low BS score of 25.

Info Density Power-words vs. Substance ratio.
9
30% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
4
20% BS
Commodity Fingerprint Detection of industry clichés/templates.
6
40% BS
Identity & Authority Expert verifiability & Schema depth.
4
27% BS

To further lower the BS score, the site should implement Medication and Organization schema to solidify its digital identity. The 2014 study citations, while foundational, should be supplemented with more recent real-world evidence from 2024 or 2025 to avoid appearing stale. Replacing slogan-only H1 tags with headers that include the ‘Number 1 Prescribed’ claim would increase heading substance. Finally, linking reference numbers directly to DOI URLs would provide a seamless proof path for healthcare professionals.

The site perfectly matches the Pharma & Biotech category, specifically focusing on naloxegol for Opioid-Induced Constipation (OIC). The presence of heavy regulatory language, mandatory Important Safety Information (ISI), and clinical trial citations confirms a high-fidelity industry alignment.

“The score of 25 is driven primarily by the high Information Density and low Semantic Drift. The Commodity Fingerprint (6) and Identity (4) pillars provided the only significant point accumulation due to the templated nature of pharma compliance and the lack of technical schema implementation.”

Verified Analysis Date: May 24, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation